Role of Desethylamiodarone in the Anticoagulant Effect of Concurrent Amiodarone and Warfarin Therapy

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Journal of Cardiovascular Pharmacology and Therapeutics

• Publication date

  2001-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/107424840100600405PMID 11907638
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range.

  2001cited by this paper
• Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: prediction of in vivo drug interactions.

  2000cited by this paper
• Optimal therapeutic range for oral anticoagulants in Japanese patients with prosthetic heart valves: a preliminary report from a single institution using conversion from thrombotest to PT-INR

  2000cited by this paper
• Potentiation of anticoagulant effect of warfarin caused by enantioselective metabolic inhibition by the uricosuric agent benzbromarone

  1999cited by this paper
• Current Antiarrhythmic Drugs

  1999cited by this paper
• Delayed Elevation of International Normalized Ratio with Concurrent Clarithromycin and Warfarin Therapy

  1998cited by this paper
• Human P450 metabolism of warfarin.

  1997cited by this paper
• Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range.

  1995cited by this paper
• Amiodarone: Reevaluation of an Old Drug

  1995cited by this paper
• Stereochemical aspects of warfarin drug interactions: Use of a combined pharmacokinetic‐pharmacodynamic model

  1994cited by this paper
• Pharmacokinetics of amiodarone: implications for drug therapy.

  1993cited by this paper
• The mechanism of the interaction between amiodarone and warfarin in humans

  1992cited by this paper
• Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions.

  1992cited by this paper
• The incidence, magnitude, and time course of the amiodarone-warfarin interaction.

  1988cited by this paper
• Interaction of amiodarone with racemic warfarin and its separated enantiomorphs in humans

  1987cited by this paper
• Clinical Pharmacokinetics and Pharmacodynamics of Warfarin

  1986cited by this paper
• ICSH/ICTH recommendations for reporting prothrombin time in oral anticoagulant control.

  1985cited by this paper
• International Committee for Standardization in Haematology International Committee on Thrombosis and Haemostasis

  1985cited by this paper
• Warfarin interaction with erythromycin.

  1984cited by this paper
• The potentiation of warfarin anticoagulation by amiodarone.

  1982cited by this paper
• Interaction between warfarin sodium and amiodarone.

  1981cited by this paper
• Dangers of amiodarone and anticoagulant treatment.

  1981cited by this paper
• Dangers of amiodarone and anticoagulant treatment.

  1981cited by this paper
• Rapid high-performance liquid chromatographic method for the measurement of amiodarone in blood plasma or serum at the concentrations attained during therapy.

  1980cited by this paper
• Studies on the optical enantiomorphs of warfarin in man

  1974cited by this paper
• Studies on the optical enantiomorphs of warfarin in man.

  1974cited by this paper

• Phenoconversion and in vivo phenotyping of hepatic cytochrome P450: Implications in predictive precision medicine and personalized therapy

  2024cites this paper
• Medication-related problems encountered in the Program of All-Inclusive Care for the Elderly: An observational study.

  2019cites this paper
• Interaction between warfarin and short-term intravenous amiodarone in intensive care unit patients after cardiac surgery

  2018cites this paper
• Impact of capecitabine and S-1 on anticoagulant activity of warfarin in patients with gastrointestinal cancer

  2016cites this paper
• Decreased levels of procoagulant phospholipids in bleeding patients treated by vitamin K antagonists.

  2016influential citation
• Synthesis and in Vitro and in Vivo Anticoagulant and Antiplatelet Activities of Amidino- and Non-Amidinobenzamides

  2016cites this paper
• Effects of amiodarone, thyroid hormones and CYP2C9 and VKORC1 polymorphisms on warfarin metabolism: a review of the literature.

  2013cites this paper
• Warfarin-Amiodarone Drug-Drug Interactions: Determination of [I]u/KI,u for Amiodarone and its Plasma Metabolites

  2012cites this paper
• Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks.

  2012cites this paper
• Increased anticoagulant activity of warfarin used in combination with doxifluridine

  2010cites this paper
• Antithrombotic activity of the novel oral anticoagulant, Tecarfarin [Sodium 3-[4-((1,1,1,3,3,3-hexafluoro-2-methylpropan-2-yloxy) carbonyl) benzyl]-2-oxo-2H-chromen-4-olate] in animal models.

  2010cites this paper
• The role of metabolites in predicting drug-drug interactions: Focus on irreversible P450 inhibition

  2010cites this paper
• The role of metabolites in predicting drug-drug interactions: focus on irreversible cytochrome P450 inhibition.

  2010cites this paper
• [Factors of therapeutic imbalance of antivitamins K and their haemorrhagic consequences in elderly].

  2008cites this paper
• Combined genetic profiles of components and regulators of the vitamin K-dependent γ-carboxylation system affect individual sensitivity to warfarin

  2006cites this paper
• Cytochrome p450 2C (CYP2C) in ischemic heart injury and vascular dysfunction.

  2006cites this paper
• Increased Sensitivity to Warfarin After Heart Valve Replacement

  2006cites this paper
• Amiodarone Analog-Dependent Effects on CYP2C9-Mediated Metabolism and Kinetic Profiles

  2006cites this paper
• Common Genetic Variants of Microsomal Epoxide Hydrolase Affect Warfarin Dose Requirements Beyond the Effect of Cytochrome P450 2C9

  2005influential citation
• Concomitant drug, dietary, and lifestyle issues in patients with atrial fibrillation receiving anticoagulation therapy for stroke prophylaxis

  2005cites this paper
• Drug Bioactivation Covalent Binding to Target Proteins and Toxicity Relevance

  2005cites this paper
• A Pharmacokinetic Study of the Combined Administration of Amiodarone and Ximelagatran, an Oral Direct Thrombin Inhibitor

  2004cites this paper
• Acenocoumarol Stabilization is Delayed in CYP2C9*3 Carriers

  2004cites this paper
• Synthesis and pharmacological evaluation of 5H-[1]benzopyrano[4,3-d]pyrimidines effective as antiplatelet/analgesic agents.

  2004cites this paper
• Cytochrome p450 enzymes and cardiovascular disease.

  2004cites this paper
• Complex Drug-Drug-Disease Interactions Between Amiodarone, Warfarin, and the Thyroid Gland

  2004cites this paper
• Amiodarone - excellent antiarrhythmic drug? (Happy end after 40 years of problems)

  2003cites this paper
• Amiodarone Interaction Time Differences with Warfarin and Digoxin

  2003cites this paper
• Therapeutic use of amiodarone and attention to its side effects

  2002cites this paper